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1. Introduction

3. Comparison of capsule and cassette fluid paths

For flow-through polishing applications membrane adsorbers have become a
well-established technology. However, there is an increasing demand for bind
1.
andIntroduction
elute purifications for larger targets as adeno- and lentiviruses, virus like
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particles
(VLP) and
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Figure 7 shows the construction of the standard membrane adsorber devices
in the 4 and 8 mm void volume optimized design. In the developed cassette
3.
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cassette
fluid paths
(Figure
8) the same flow
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as in the existing
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feed travels
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through
Figure
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In the
cassette (Fig. 6) the same flow principle is applied as in the
existing capsules as feed flows perpendicular through the membrane and through void volume
optimized fluid channels.
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Figure 1: Typical modes of operations and applications for membrane adsorbers in the biopharmaceutical industry.
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But capture applications with such devices suffered from the current size
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been tested for scale-up and flow performance in comparison with void volume
optimized capsules. The goals are to create a system up to 20 L membrane
But capture applications with such devices suffered from the current size limitation of
volume, be able adapt exactly to the size needed (modular), using the same
5 liters e.g. in the Sartobind® Q or S Jumbo 5 L. (Fig. 2a) Here we describe a modular
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7: Design and flow path of void volume optimized
Figure 5:
adsorber capsules in 8 mm (left) and 4 mm (right) bed height.

8: Design and flow path of void volume optimized
Figure 6:
adsorber cassettes in 8 mm (left) and 4 mm (right) bed height.

4. Scaleability
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The pressure-flow dependency as well as the break through behaviour was
analyzed
comparing Sartobind® Q 1.2 L size with 10 + 1.6 L cassettes in terms
2.0
of pressure and flow (see figure 9). Flow performance of capsules and
cassettes
are on the same level.
1.6
nano 3 mL

membrane volume which can be optionally expanded to ~100 liter and, be able adapt
exactly to the size needed (modular), using the same 4 and 8 mm bed height as the
capsules and membranes for single- or intra batch re-use.

2. The cassette design: 2 membrane stacks 4 | 8 mm

5 inch 150 mL

In capsules the membrane is rolled up. To achieve the same flow pattern in
the cassette, a cut through a capsule suggests two stacks of membrane with
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Figure 2b: Design for the cassette is derived from the capsule
by cutting and creating thus two membrane stacks.

Figure 2a: Sartobind® Jumbo 5 L

Figure 2b: Design for the cassette is derived from the capsule by cutting
Figure 2a: Sartobind® Jumbo 5 L as largest
Figure
3
shows
the
realized
cassette
a two
sizemembrane
of 634stacks.
+ 387 + 49 mm and
andwith
creating
adsorber size

a dry weight of 4.5 kg. The cassette can be assembled in a holder which
accommodates up to 13 cassettes (20.8 L) which are run with one manifold
Figure 3 shows the realized cassette with a size of 634 + 387 + 47 mm and a dry weight
feeding the liquid in the upstream distribution channels and one manifold
of 4.9 kg (6.0 kg wet). The cassette can be assembled in a pilot filter holder which
of the downstream channel.

accommodates up to 13 cassettes (20.8 L, Fig. 4c) and are run with one manifold feeding the liquid in the upstream distribution channels and one manifold of the downstream
channel (Fig. 4a). A process holder has been designed for up to ~100 L membrane (Fig 4b).
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Cassette prototype A and B as well as 3 + 1.6 L displayed the same shape of
breakthrough as the optimized capsule (1.2 L). The non (void volume) optimized
®
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Sulfated Cellulose – Influenza A/Puerto Rico/8/1934 (H1N1) virus particles/mL

Anion exchanger Q – Adenovirus Type 5 virus particles/mL
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6. Summary
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The design limitation of capsules to 5 L membrane volume has been overruled
by a cassette system which allows the setup of modular membranes in discrete
volumes up to the 20 L range. The results confirm the scalability of void volume
optimized membrane chromatography devices with cassettes following the same
design principles and adsorber flow performance without compromising on back
pressure.
Column volumes: 1.0 mL (Sartobind Q), 20 mL (Resin Q)
Column volumes: 0.08 mL (SC), 0.18 mL (Resin A, Resin B)
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Figure 3: Design of Sartobind® cassette
OUT

Figure 4a: Symmetrical manifolds at both ends of cassette pack
are needed to connect the setup to a chromatography skid
Figure 4: Symmetrical manifolds at both ends of cassette
pack (picture right showing 10 + 1.6 L cassettes) are needed
to connect the setup to a chromatography skid
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Table 1: Existing Sartobind® membrane chromatography capsule portfolio with 4 mm and 8 mm bed height and Cassette
membrane volumes
Figure 4b: 100 L Process Holder
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Table 1: Existing Sartobind membrane chromatography capsule portfolio with 4 mm and 8 mm bed height and Cassette
membrane volumes
®

Sartobind SC

Resin SC A

Resin SC B

Flow rate: 3.75 CV/min (SC), 0.67 CV/min (Resin A), 1 CV/min (Resin B)
Feed: 6 × 1007 VP/mL, 30 kHAU/mL in 10 mM TRIS, pH 7.4
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Figure 4c: 13 Cassettes (20.8 L) in the Pilot Filter Holder
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